Health-related quality of life became worse in short-term during treatment in head and neck cancer patients: a prospective study

do Nascimento Santos Lima, Emanuelle; Ferreira, Isabela Borges; Lajolo, Paula Philbert; Paiva, Carlos Eduardo; de Paiva Maia, Yara Cristina; das Graças Pena, Geórgia

doi:10.1186/s12955-020-01543-5

Table 2 QLQ-C30:Scores of Quality of life of patients with head and neck cancer during antineoplastic treatment (n = 63)

Quality of Life domains	T0		T1		T2		*p-value*	∆ T1-T0 n (%)	∆ T2-T1 n (%)	∆ T2-T0 n (%)
Quality of Life domains	Mean (SD)	Median (p₂₅-p₇₅)	Mean (SD)	Median (p₂₅-p₇₅)	Mean (SD)	Median (p₂₅-p₇₅)	*p-value*	≥ ± 10 score points n (%)
Global health status	67.46 (20.61)	66.66 (50.00–83.33)	69.31 (21.62)	66.66 (50.00–83.33)	61.12 (21.40)	66.66 (50.00–83.33)	0.622	13 (20.6)	20 (31.7)	18 (21.6)
Physical function	80.39 (19.26)	90 (65–100)	81.19 (18.24)	85 (70–100)	79.12 (18.82)	80 (60–100)	0.909	16 (25.4)	18 (28.6)	22 (34.9)
Role function	79.36 (30.92)	100 (66.66–100)	70.10 (35.05)	83.33 (50–100)	67.98 (32.83)	66.66 (50–100)	0.009	23 (36.5)	21 (33.3)	29 (46.0)
Emotional function	68.12 (29.31)	75 (41.66–91.66)	69.84 (29.19)	75 (50–100)	69.70 (28.60)	75 (50–100)	0.986	19 (30.2)	18 (28.6)	19 (30.2)
Cognitive function	78.04 (29.45)	100 (50–100)	80.42 (27.19)	100 (66.66–100)	83.86 (27.10)	100 (83.33–100)	0.035	12 (19.0)	11 (17.5)	8 (12.7)
Social function	85.44 (24.40)	100 (66.66–100)	80.95 (29.00)	100 (66.66–100)	81.48 (29.65)	100 (66.66–100)	0.619	17 (27.0)	11 (17.5)	17 (27.0)
Fatigue	27.51 (31.03)	11.11 (0.0–44.44)	32.62 (29.65)	22.22 (11.11–55.55)	30.15 (28.46)	22.22 (0.0–44.44)	0.010^a	30 (47.6)	28 (44.4)	33 (52.4)
Nausea and vomiting	8.46 (20.71)	0.0 (0.0–0.0)	19.57 (24.04)	16.66 (0.0–33.33)	13.22 (25.07)	0.0 (0.0–16.66)	< 0.001^b	30 (47.6)	9 (14.3)	15 (23.8)
Pain	32.27 (33.84)	16.66 (0.0–50)	30.68 (28.74)	33 (0.0–50)	27.77 (31.82)	16.66 (0.0–50)	0.799	23 (36.5)	20 (31.7)	22 (34.9)
Dyspnoea	11.11 (26.77)	0.0 (0.0–0.0)	13.22 (29.04)	0.0 (0.0–0.0)	13.22 (27.78)	0.0 (0.0–0.0)	0.821	8 (12.7)	8 (12.7)	9 (14.3)
Insomnia	29.10 (39.02)	0.0 (0.0–66.66)	22.22 (35.92)	0.0 (0.0–33.33)	25.39 (37.25)	0.0 (0.0–66.66)	0.630	10 (15.9)	13 (20.6)	11 (17.5)
Appetite loss	25.92 (36.63)	0.0 (0.0–66.66)	43.91 (44.32)	33.33 (0.0–100)	35.97 (43.29)	0.0 (0.0–100)	0.015	28 (44.4)	12 (19.0)	23 (36.5)
Constipation	24.86 (38.31)	0.0 (0.0–33.33)	39.15 (41.71)	33.33 (0.0–100)	37.03 (41.95)	33.33 (0.0–66.66)	0.023	24 (38.1)	18 (28.6)	21 (33.3)
Diarrhea	1.05 (5.89)	0.0 (0.0–0.0)	6.34 (20.61)	0.0 (0.0–0.0)	6.34 (23.07)	0.0 (0.0–0.0)	0.190	7 (11.1)	5 (7.9)	6 (9.5)
Financial difficulties	34.39 (41.02)	0.0 (0.0–66.66)	34.92 (42.09)	0.0 (0.0–100)	39.68 (43.93)	33.33 (0.0–100)	0.744	14 (22.2)	14 (22.2)	19 (30.2)

P-values followed by letters differed statistically according to the post hoc test at the 5% probability level (Friedman test and Dunn post hoc test ajusted by Bonferroni: ^a difference between T0 and T2; ^b difference between T0 and T1. ∆ T1-T0, ∆ T2-T1 and ∆ T2-T0 ≥ 10 or ≤ −10 score points: clinically significant negative difference

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us